Hemostemix Sale Purchase Of Stock vs End Period Cash Flow Analysis
HEM Stock | CAD 0.08 0.01 5.88% |
Hemostemix financial indicator trend analysis is much more than just examining Hemostemix latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Hemostemix is a good investment. Please check the relationship between Hemostemix Sale Purchase Of Stock and its End Period Cash Flow accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Hemostemix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
Sale Purchase Of Stock vs End Period Cash Flow
Sale Purchase Of Stock vs End Period Cash Flow Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Hemostemix Sale Purchase Of Stock account and End Period Cash Flow. At this time, the significance of the direction appears to have weak relationship.
The correlation between Hemostemix's Sale Purchase Of Stock and End Period Cash Flow is 0.31. Overlapping area represents the amount of variation of Sale Purchase Of Stock that can explain the historical movement of End Period Cash Flow in the same time period over historical financial statements of Hemostemix, assuming nothing else is changed. The correlation between historical values of Hemostemix's Sale Purchase Of Stock and End Period Cash Flow is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Sale Purchase Of Stock of Hemostemix are associated (or correlated) with its End Period Cash Flow. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when End Period Cash Flow has no effect on the direction of Sale Purchase Of Stock i.e., Hemostemix's Sale Purchase Of Stock and End Period Cash Flow go up and down completely randomly.
Correlation Coefficient | 0.31 |
Relationship Direction | Positive |
Relationship Strength | Very Weak |
Sale Purchase Of Stock
End Period Cash Flow
Most indicators from Hemostemix's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Hemostemix current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Hemostemix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. Issuance Of Capital Stock is likely to climb to about 2.3 M in 2024, whereas Selling General Administrative is likely to drop slightly above 1.3 M in 2024.
Hemostemix fundamental ratios Correlations
Click cells to compare fundamentals
Hemostemix Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Hemostemix fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 104.3K | 2.3M | 563.0K | 465.3K | 313.8K | 298.1K | |
Other Current Liab | 2.1M | 3.2M | 1.0M | 2.6M | 3.0M | 3.2M | |
Total Current Liabilities | 4.1M | 3.4M | 4.4M | 2.6M | 2.9M | 2.4M | |
Total Stockholder Equity | (4.0M) | (1.1M) | (5.3M) | (6.8M) | (7.4M) | (7.0M) | |
Net Tangible Assets | 487.8K | (4.0M) | (1.1M) | (6.8M) | (6.1M) | (5.8M) | |
Net Debt | 2.0M | (83.0K) | 1.3M | 4.0M | 4.2M | 4.4M | |
Retained Earnings | (41.5M) | (49.2M) | (55.5M) | (60.8M) | (63.3M) | (60.1M) | |
Accounts Payable | 2.1M | 3.2M | 4.4M | 2.4K | 2.9M | 1.6M | |
Cash | 24.1K | 258.0K | 219.4K | 135.7K | 155.4K | 147.6K | |
Non Current Assets Total | 4.5K | 2.0K | 902.0 | 407.0 | 184.0 | 174.8 | |
Cash And Short Term Investments | 24.1K | 258.0K | 219.4K | 135.7K | 155.4K | 147.6K | |
Net Receivables | 75.8K | 2.1M | 342.7K | 138.9K | 25.1K | 23.8K | |
Common Stock Shares Outstanding | 15.0M | 32.2M | 57.4M | 70.0M | 82.5M | 86.6M | |
Liabilities And Stockholders Equity | 104.3K | 2.3M | 563.0K | 465.3K | 313.8K | 298.1K | |
Inventory | (88.2K) | (13.3K) | (45.5K) | (342.7) | (394.1) | (413.81) | |
Other Current Assets | 13.3K | 45.5K | 342.7 | 190.3K | 133.1K | 101.6K | |
Other Stockholder Equity | 6.0M | 8.7M | 10.1M | 10.2M | 11.9M | 12.5M | |
Total Liab | 4.1M | 3.4M | 5.8M | 7.2M | 7.7M | 8.1M | |
Total Current Assets | 99.8K | 2.3M | 562.1K | 464.9K | 313.6K | 297.9K | |
Accumulated Other Comprehensive Income | 439.7K | 1.5M | 1.5M | 2.7M | 1.5M | 1.5M | |
Net Invested Capital | (2.0M) | (923.7K) | (3.8M) | (2.6M) | (3.0M) | (2.9M) | |
Net Working Capital | (4.0M) | (1.1M) | (3.8M) | (2.2M) | (2.6M) | (2.4M) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Hemostemix Stock Analysis
When running Hemostemix's price analysis, check to measure Hemostemix's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hemostemix is operating at the current time. Most of Hemostemix's value examination focuses on studying past and present price action to predict the probability of Hemostemix's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hemostemix's price. Additionally, you may evaluate how the addition of Hemostemix to your portfolios can decrease your overall portfolio volatility.